# A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

> **NCT04238975** · PHASE2 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 213 (estimated)

## Conditions studied

- Tetanus
- Diphtheria
- Whooping Cough

## Interventions

- **BIOLOGICAL:** GC3111 vaccine
- **BIOLOGICAL:** Boostrix® vaccine

## Key facts

- **NCT ID:** NCT04238975
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-14
- **Primary completion:** 2021-02
- **Final completion:** 2021-05
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238975, "A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04238975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*